Cargando…

Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is a premalignant condition and a well-documented risk factor for cholangiocarcinoma (CCA) which is the most common malignancy in this setting and the leading cause of deaths in the recent years, with an increasing incidence. PSC-associated CCA has a geographical...

Descripción completa

Detalles Bibliográficos
Autores principales: Saffioti, Francesca, Mavroeidis, Vasileios K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529934/
https://www.ncbi.nlm.nih.gov/pubmed/34721770
http://dx.doi.org/10.4251/wjgo.v13.i10.1336
_version_ 1784586567928512512
author Saffioti, Francesca
Mavroeidis, Vasileios K
author_facet Saffioti, Francesca
Mavroeidis, Vasileios K
author_sort Saffioti, Francesca
collection PubMed
description Primary sclerosing cholangitis (PSC) is a premalignant condition and a well-documented risk factor for cholangiocarcinoma (CCA) which is the most common malignancy in this setting and the leading cause of deaths in the recent years, with an increasing incidence. PSC-associated CCA has a geographical distribution that follows the incidence of PSC, with an observed ascending gradient from the Eastern to the Western and from the Southern to the Northern countries. It may arise at any location along the biliary tree but is most common in the perihilar area. Patients with PSC and intrahepatic or perihilar CCA are typically not suitable for liver resection, which is otherwise the treatment of choice with curative intent in patients with resectable tumours, providing a radical resection with clear margins can be achieved. This largely relates to the commonly advanced stage of liver disease at presentation, which allows consideration for liver resection only for a very limited number of suitable patients with PSC. On the other hand, remarkable progress has been reached in the last decades with the implementation of a protocol combining neoadjuvant chemoradiation and orthotopic liver transplantation (OLT) for the treatment of perihilar CCA, within specific criteria. Excellent results have been achieved particularly for PSC patients with this cancer, who seem to benefit the most from this treatment, having converted this into an accepted indication for transplantation and the standard of care in several experienced centres. Intrahepatic CCA as an indication for OLT remains controversial and has not been accepted given disappointing previous results. However, as recent studies have shown favourable outcomes in early intrahepatic CCA, it may be that under defined criteria, OLT may play a more prominent role in the future. Distal CCA in the context of PSC requires aggressive surgical treatment with curative intent, when feasible. This review provides insight about particular features of CCA in the setting of PSC, with a main focus on its incidence, considerations relating to its anatomical location and implications to treatment and outcomes, through the viewpoint of historical evolution of management, and future perspectives.
format Online
Article
Text
id pubmed-8529934
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-85299342021-10-28 Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis Saffioti, Francesca Mavroeidis, Vasileios K World J Gastrointest Oncol Review Primary sclerosing cholangitis (PSC) is a premalignant condition and a well-documented risk factor for cholangiocarcinoma (CCA) which is the most common malignancy in this setting and the leading cause of deaths in the recent years, with an increasing incidence. PSC-associated CCA has a geographical distribution that follows the incidence of PSC, with an observed ascending gradient from the Eastern to the Western and from the Southern to the Northern countries. It may arise at any location along the biliary tree but is most common in the perihilar area. Patients with PSC and intrahepatic or perihilar CCA are typically not suitable for liver resection, which is otherwise the treatment of choice with curative intent in patients with resectable tumours, providing a radical resection with clear margins can be achieved. This largely relates to the commonly advanced stage of liver disease at presentation, which allows consideration for liver resection only for a very limited number of suitable patients with PSC. On the other hand, remarkable progress has been reached in the last decades with the implementation of a protocol combining neoadjuvant chemoradiation and orthotopic liver transplantation (OLT) for the treatment of perihilar CCA, within specific criteria. Excellent results have been achieved particularly for PSC patients with this cancer, who seem to benefit the most from this treatment, having converted this into an accepted indication for transplantation and the standard of care in several experienced centres. Intrahepatic CCA as an indication for OLT remains controversial and has not been accepted given disappointing previous results. However, as recent studies have shown favourable outcomes in early intrahepatic CCA, it may be that under defined criteria, OLT may play a more prominent role in the future. Distal CCA in the context of PSC requires aggressive surgical treatment with curative intent, when feasible. This review provides insight about particular features of CCA in the setting of PSC, with a main focus on its incidence, considerations relating to its anatomical location and implications to treatment and outcomes, through the viewpoint of historical evolution of management, and future perspectives. Baishideng Publishing Group Inc 2021-10-15 2021-10-15 /pmc/articles/PMC8529934/ /pubmed/34721770 http://dx.doi.org/10.4251/wjgo.v13.i10.1336 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/ -Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Review
Saffioti, Francesca
Mavroeidis, Vasileios K
Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis
title Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis
title_full Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis
title_fullStr Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis
title_full_unstemmed Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis
title_short Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis
title_sort review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529934/
https://www.ncbi.nlm.nih.gov/pubmed/34721770
http://dx.doi.org/10.4251/wjgo.v13.i10.1336
work_keys_str_mv AT saffiotifrancesca reviewofincidenceandoutcomesoftreatmentofcholangiocarcinomainpatientswithprimarysclerosingcholangitis
AT mavroeidisvasileiosk reviewofincidenceandoutcomesoftreatmentofcholangiocarcinomainpatientswithprimarysclerosingcholangitis